Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

April 30, 2014

Conditions
Multiple Myeloma
Interventions
COMBINATION_PRODUCT

tandem autologous transplantation

"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 \& 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Guido Tricot

OTHER

NCT00670631 - Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | Biotech Hunter | Biotech Hunter